Bristol-Myers Squibb Stock Forecast for 2023 - 2025 - 2030
Updated on 04/19/2024
Bristol-Myers Squibb Stock Forecast and Price Target
If the average 2024 price target of $55.00 recently set by ten prominent experts for Bristol-Myers Squibb is met, there would be a potential upside of approximately 13.87% from the last closing price in April, 2024. The high estimate is $75.00, and the low is $40.00. If you're looking for information on Bristol-Myers Squibb stock, consider checking out the forecasts for comparable firms such as NYSE:JNJ.
13.87% Upside
Bristol-Myers Squibb Fair Value Forecast for 2023 - 2025 - 2030
In the last four years, Bristol-Myers Squibb's Price has decreased by 100.00%, going from $60.79 to $0.00. In the next year, analysts believe that Fair Value will reach $80.33 – an increase of 100.00%. For the next seven years, the forecast is for Fair Value to grow by 100.00%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| LLY Stock Forecast | Eli Lilly and | Outperform |
16
|
$745.95 | Buy/Sell | $636.99 | 12.27% |
| NOVO B Stock Forecast | Novo Nordisk A/S | Outperform |
12
|
kr862.70 | Buy/Sell | kr696.07 | 11.28% |
| XOM Stock Forecast | Exxon Mobil Corp | Outperform |
4
|
$118.52 | Buy/Sell | $124.27 | 8.42% |
| JNJ Stock Forecast | Johnson & Johnson | Outperform |
9
|
$145.74 | Buy/Sell | $174.55 | 16.65% |
| MRK Stock Forecast | Merck | Outperform |
2
|
$125.23 | Buy/Sell | $130.51 | 11.00% |
Bristol-Myers Squibb Revenue Forecast for 2023 - 2025 - 2030
In the last three years, Bristol-Myers Squibb's Revenue has grown, rising from $42.52B to $45.01B – a growth of 5.85%. In the next year, analysts believe that Revenue will reach $50.13B – an increase of 11.38%. By 2030, professionals predict that Bristol-Myers Squibb's Revenue will decrease by 18.02%, to $36.90B.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| 857 Stock Forecast | PetroChina Company | Outperform |
3
|
HK$7.32 | Buy/Sell | HK$6.10 | -5.33% |
| AZN Stock Forecast | AstraZeneca PLC | Outperform |
17
|
£109.14 | Buy/Sell | £165.99 | 48.27% |
| NOVN Stock Forecast | Novartis | Hold |
10
|
CHF84.52 | Buy/Sell | CHF105.00 | 24.59% |
.jpg)
Bristol-Myers Squibb Dividend per Share Forecast for 2023 - 2025 - 2030
Bristol-Myers Squibb's Dividend per Share has grown In the last three years, rising from $1.84 to $2.31 – a growth of 25.54%. In the next year, analysts believe that Dividend per Share will reach $2.37 – an increase of 2.60%. In 2030, the professionals' prediction is that BMY's Dividend per Share will decrease by 9.09%, reaching $2.10.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| DHR Stock Forecast | Danaher | Outperform |
10
|
$236.36 | Buy/Sell | $260.33 | 14.23% |
| PFE Stock Forecast | Pfizer | Outperform |
2
|
$25.39 | Buy/Sell | $32.87 | 20.13% |
| AMGN Stock Forecast | Amgen | Outperform |
4
|
$262.75 | Buy/Sell | $303.65 | 20.74% |
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| MDT Stock Forecast | Medtronic | Outperform |
11
|
$79.19 | Buy/Sell | $92.47 | 20.60% |
| BP. Stock Forecast | BP p.l.c. | Outperform |
9
|
£5.12 | Buy/Sell | £7.50 | 45.90% |
| 386 Stock Forecast | China Petroleum & Chemical | Outperform |
3
|
HK$4.58 | Buy/Sell | HK$5.04 | 5.02% |
Bristol-Myers Squibb EBITDA Forecast for 2023 - 2025 - 2030
In the last three years, Bristol-Myers Squibb's EBITDA has grown by 1.30%, rising from $18.18B to $18.42B. For the next year, analysts predict that EBITDA will reach $21.76B – an increase of 18.15%. In 2030, professionals predict that Bristol-Myers Squibb's EBITDA will decrease by 24.62%, reaching $13.89B.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| GSK Stock Forecast | GSK | Outperform |
12
|
£15.84 | Buy/Sell | £17.30 | 23.11% |
| BDX Stock Forecast | Becton Dickinson and Co | Outperform |
9
|
$233.15 | Buy/Sell | $284.47 | 20.09% |
| 4519 Stock Forecast | Chugai Pharmaceutical | Outperform |
6
|
¥5.09k | Buy/Sell | ¥4.92k | 20.83% |
Bristol-Myers Squibb EBIT Forecast for 2023 - 2025 - 2030
In the last three years, Bristol-Myers Squibb's EBIT has grown, moving from $7.75B to $8.65B – an increase of 11.61%. In the next year, analysts predict that EBIT will jump to $20.77B – up 140.06% from the current level. Looking ahead to seven years, experts forecast that EBIT will grow by 75.87%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| MMM Stock Forecast | 3M | Hold |
10
|
$91.48 | Buy/Sell | $109.39 | 9.31% |
| BAS Stock Forecast | BASF | Outperform |
12
|
51.07€ | Buy/Sell | 49.50€ | 9.65% |
| MRNA Stock Forecast | Moderna | Outperform |
16
|
$102.00 | Buy/Sell | $135.42 | 21.96% |
Bristol-Myers Squibb EPS Price Prediction Forecast for 2023 - 2025 - 2030
In the last four years, Bristol-Myers Squibb's EPS has decreased by 100.00%, going from $6.44 to $0.00. In the next year, analysts believe that EPS will reach $8.51 – an increase of 100.00%. For the next seven years, the forecast is for EPS to grow by 100.00%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| A Stock Forecast | Agilent Technologies | Outperform |
10
|
$132.44 | Buy/Sell | $138.82 | 14.39% |
| CTVA Stock Forecast | Corteva | Outperform |
12
|
$53.96 | Buy/Sell | $61.72 | 18.61% |
| BEI Stock Forecast | Beiersdorf | Outperform |
17
|
135.60€ | Buy/Sell | 137.41€ | 9.88% |
.jpg)